Arthur Zanni 
Which is the first pharmaceutical industry in Italy? The question is often asked of interlocutors who do not know him and Arturo Zanni, managing director and managing director of Sanofi, almost never gets the right answer. Which obviously corresponds to the name of the French group that has become a case in international markets for its size (33 billion in turnover with 110,000 employees) and for its global strategies with first place in China and the right decision to invest in a decisive acquisition such as Genzyme, among the protagonists of biotechnology.
The impact of all this on the share price on the Paris Stock Exchange, the best for two years of the index Cac 40, justify Zanni's optimism also for the Italian market, where Sanofi boasts the most important industrial structure in the sector with six factories and 1,400 production workers, exported for 1,80% all over the world, from Enterogermina produced in the Origgio plants, in province of Varese, to Maalox packaged since 2013 in the warehouses of Scoppito (Aquila), up to the antimalarial medicines that are prepared in the historic site of Garessio, in the mountains of Cuneo, where the story of Lepetit began more than a century ago, a company that later merged in Sanofi in a chain of acquisitions which over time have included the merger with Aventis.
The French multinational has a strong presence in diabetes care, oncology (with offices in Cambridge, Massachusetts, and Vitry in France), cardiovascular and nervous system diseases, as well as dealing with vaccines with Sanofi Pasteur, animal health with Merial , food supplements, self-medication drugs and Zentiva generics (the third largest company in the sector), which will also be increasingly supported in Italy.
Well, for the CEO of the Italian branch, who has been at the top with full powers for just over a year (he took over from Daniel Lapeyre, who remained president) in the Milan headquarters with an army of 3,000 employees in all, the time has come to know the strength of the group at all levels after some controversy with the unions on the reduction of researchers.
